We report on long-term outcomes of 267 patients (pts) with chronic myeloid leukemia (CML)
treated with imatinib administered as initial therapy. The median follow-up time was 11.4 …

For almost 10 years imatinib has been the therapeutic standard of chronic myeloid leukemia.
The introduction of other tyrosine kinase inhibitors (TKIs) raised a debate on treatment …

Background Imatinib, a selective BCR-ABL1 kinase inhibitor, improved the prognosis for
patients with chronic myeloid leukemia (CML). We conducted efficacy and safety analyses …

Imatinib mesylate is considered standard of care for first-line treatment of chronic phase
chronic myeloid leukemia (CML-CP). In the phase III, randomized, open-label International …

Abstract Abstract 1693 Background: Outcomes of CML chronic phase (CP) pts treated in
clinical trials are frequently perceived to not be representative of those treated outside of …

Imatinib therapy for chronic myeloid leukemia: where do we go now? - Abstract - Europe PMC
Sign in | Create an account https://orcid.org Europe PMC Menu About Tools Developers Help …

Imatinib, the first BCR/ABL kinase inhibitor approved for the treatment of chronic myeloid
leukemia (CML), has changed the long-term outcome of patients affected by this disease …

Background Imatinib treatment significantly improves survival in patients with chronic
myeloid leukaemia (CML), but little is known about whether treatment can safely be …

Abstract Introduction Outcomes of CML-CP patients treated in clinical trials are frequently
perceived to be not representative of those treated outside of clinical trials. Patients and …

Background Imatinib was the first tyrosine kinase inhibitor that has revolutionized the
therapy of chronic myeloid leukemia. It binds breakpoint cluster region–Abelson kinase …